SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K Current Report, dated December 29, 2017 (filed January 2, 2018), concerns India Globalization Capital, Inc. (also referenced as IGC Pharma, Inc. in metadata). The filing addresses the results of shareholder votes at the adjourned 2016-2017 Annual Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
- Proposal Three (Approved): Shareholders approved the grant of 1,900,000 shares of common stock to current and new employees, advisors, directors, and consultants. The grant is subject to metrics including performance, vesting, and incentives set by the Board or CEO.
- Voting Statistics for Proposal Three:
- For: 13,513,445 shares
- Against: 441,330 shares
- Abstain: 63,233 shares
- Total Voted: 14,018,008 shares (approximately 50.24% of 27,905,272 shares outstanding).
- Proposal Four (Adjourned): Voting on the issuance of up to 2,000,000 shares to Bricoleur Partners, L.P. was adjourned again to February 28, 2018, to allow additional time for stockholder voting.
Outlook, Risks, and Management Commentary
Management is continuing to solicit proxies specifically for Proposal Four during the adjournment period. Stockholders who have already voted do not need to recast their votes; previously submitted proxies will be voted at the adjourned meeting unless revoked. The filing includes a press release dated January 2, 2018, as Exhibit 99.1.
Investor Verification Checklist
- Verify the final outcome of Proposal Four (issuance to Bricoleur Partners) after the February 28, 2018, adjourned meeting.
- Confirm the specific vesting schedules and performance metrics for the 1,900,000 shares approved under Proposal Three.
- Review the attached press release (Exhibit 99.1) for additional context on the adjournment rationale.
- Check subsequent filings for any updates on the company's financial status, as this 8-K contains no financial data.